Galera Therapeutics Statistics
Share Statistics
Galera Therapeutics has 54.39M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 54.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 39.94M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 2.12M, so 3.9% of the outstanding shares have been sold short.
| Short Interest | 2.12M |
| Short % of Shares Out | 3.9% |
| Short % of Float | 5.32% |
| Short Ratio (days to cover) | 1.16 |
Valuation Ratios
The PE ratio is -0.11 and the forward PE ratio is -0.04.
| PE Ratio | -0.11 |
| Forward PE | -0.04 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -0.05 |
| P/FCF Ratio | -0.14 |
| PEG Ratio | n/a |
Enterprise Valuation
Galera Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.36, with a Debt / Equity ratio of -0.01.
| Current Ratio | 4.36 |
| Quick Ratio | 4.36 |
| Debt / Equity | -0.01 |
| Total Debt / Capitalization | -0.96 |
| Cash Flow / Debt | -35.88 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.45% and return on capital (ROIC) is 36.13%.
| Return on Equity (ROE) | 0.45% |
| Return on Assets (ROA) | -2.26% |
| Return on Capital (ROIC) | 36.13% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -8.44M |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -78.1% in the last 52 weeks. The beta is 1.99, so Galera Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.99 |
| 52-Week Price Change | -78.1% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.12 |
| Relative Strength Index (RSI) | 29.08 |
| Average Volume (20 Days) | 150.34K |
Income Statement
In the last 12 months, Galera Therapeutics had revenue of $0 and earned -$59.08M in profits. Earnings per share was $-1.33.
| Revenue | 0 |
| Gross Profit | -259.00K |
| Operating Income | -46.95M |
| Net Income | -59.08M |
| EBITDA | -46.69M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.33 |
Balance Sheet
The company has $18.26M in cash and $1.25M in debt, giving a net cash position of $17.01M.
| Cash & Cash Equivalents | 18.26M |
| Total Debt | 1.25M |
| Net Cash | 17.01M |
| Retained Earnings | -437.41M |
| Total Assets | 16.38M |
| Working Capital | 9.84M |
Cash Flow
In the last 12 months, operating cash flow was -$44.85M and capital expenditures -$59.00K, giving a free cash flow of -$44.91M.
| Operating Cash Flow | -44.85M |
| Capital Expenditures | -59.00K |
| Free Cash Flow | -44.91M |
| FCF Per Share | -1.01 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
GRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4433.33% |
| FCF Yield | -2752.05% |
Analyst Forecast
Currently there are no analyst rating for GRTX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -42.8 |
| Piotroski F-Score | 2 |